1. Pauly et al. Multiple endpoint analysis of BAK-preserved and unpreserved anti-allergic eye drops on the new 3D-reconstituted corneal epithelial model. Molecular Vision 2011; 17:745-755;
2. Beden et al. A comparative study of the ocular tolerance after administration of antiallergic eyedrops with r without a preservative. 2004; 59 (2): 259-64;
3. Hong J., Bielory L. Allergy to ophthalmic preservatives Curr Opin Allergy Clin Immunol 2009 Oct;9(5):447-53. 8.
4. Charakterystyka Produktu Leczniczego z dnia 01.11.2015;
5.Torkildsen et al. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a singlecenter, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis. Clin Ther 2008; 30: 1272-1282;
6. Abelson et al. Efficacy of Ketotifen Fumarate 0.025% ophthalmic solution compared with placebo in the Conjunctival Allergen Challenge Model. Arch Ophthalmol 2003; 121: 626-630;
7. Greiner et al. A placebo-controlled comparison of Ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin Ther 2003b; 25: 1988-2005;